As a Data Scientist at BridgeBio, you are not just building models; you are accelerating the delivery of transformative medicines to patients with genetic diseases. This role sits at the intersection of complex clinical data, statistical rigor, and business strategy. Your work directly informs critical decision-making across the drug development lifecycle, from early-stage research to clinical operations and regulatory strategy.
You will be expected to bridge the gap between technical complexity and actionable insights. By collaborating with clinical operations, data management, and statistical teams, you will tackle high-stakes problems that require both precision and a deep understanding of the pharmaceutical landscape. Success in this role requires a unique blend of technical expertise and the ability to articulate complex findings to stakeholders who are focused on the mission of improving patient lives.
BridgeBio is a mission-driven organization. Your interviewers will look for evidence that your technical work is consistently anchored in the goal of clinical impact.
Preparation focus
editorialNo round sequence has been reported for this company, so work the categories below and confirm the format with your recruiter.
What to demonstrate
- Breadth across SQL, experimentation and product reasoning
- Ability to state assumptions before choosing a method
How to prepare
- Drill the practice exercises below and time yourself
- Prepare three quantified stories about decisions you drove
PracHub editorial advice for the preparation topics above.
Ignoring clustering by provider, facility, or site
Patients within a provider panel, and subjects within a trial site, are correlated on both case mix and practice pattern. Standard errors computed as if observations were independent are too narrow by roughly the design effect, 1 + (m - 1) * ICC, where m is the average cluster size. With 50 patients per provider and an intracluster correlation of only 0.02, variance is understated by about a factor of two, which manufactures significant provider differences out of noise. Cluster-robust errors or a random intercept per provider, and cluster-level randomisation when you design the test, are the corrections.
Treating clinical measurements as missing at random
A lab result, a vital sign, or a screening exists because someone ordered it, and ordering tracks suspicion of disease, visit frequency, and site workflow. Imputing the mean or dropping incomplete rows biases the population estimate and can flip the sign of an association, because the untested are systematically healthier or systematically disengaged. The presence indicator is often more predictive than the value, which is a warning sign rather than a feature win: a model that learns test ordering will not transfer to a site with different protocols.
Reaching for a model before the target metric exists
Before naming an algorithm, write down the label, the prediction time, and the action that changes when the score crosses a threshold. If you cannot say what decision the output drives, any modelling choice is guesswork dressed up as method.
Reading a dozen metrics with no multiplicity control
Nominate one primary metric before launch and treat the rest as guardrails or exploratory, with Bonferroni or Benjamini-Hochberg applied when you intend to make claims from them. Twenty independent tests at 0.05 under the null produce at least one false positive about 64 percent of the time.
Choose a category, try a prompt, then open its approach, worked solution or follow-up when you need it.
How do you ensure reproducibility and data integrity in your analytica…
How do you ensure reproducibility and data integrity in your analytical workflows?
Approach
- Translate the result into the decision it informs, in one plain sentence.
- Sanity-check the answer against a simple bound or a simulated case.
- Say what the estimate is of, and over what population it generalises.
Follow-up
- What sample size would you need to detect an effect half this size?
- Which assumption here is most likely to be violated in practice?
How would you handle missing data in a clinical trial dataset?
How would you handle missing data in a clinical trial dataset?
Approach
- Say what the estimate is of, and over what population it generalises.
- Quantify uncertainty explicitly rather than reporting a point estimate alone.
- Sanity-check the answer against a simple bound or a simulated case.
Follow-up
- How would you explain this result to someone who does not know statistics?
- What sample size would you need to detect an effect half this size?
Discuss the trade-offs between different regression models in the cont…
Discuss the trade-offs between different regression models in the context of drug efficacy analysis.
Approach
- Pick an evaluation metric that matches the cost of each error type, not a default.
- Say how the offline result would be validated online before it is trusted.
- Set a baseline first, so any model has something honest to beat.
Follow-up
- What would you monitor after launch to know the model is still valid?
- How would you choose the decision threshold, and who owns that choice?
How do you validate the performance of a model when the sample size is…
How do you validate the performance of a model when the sample size is limited?
Approach
- Pick an evaluation metric that matches the cost of each error type, not a default.
- Say how the offline result would be validated online before it is trusted.
- Frame the prediction: the label, the moment of prediction, and the action it triggers.
Follow-up
- What would you monitor after launch to know the model is still valid?
- Where could label leakage enter this setup?
Collapse claim versions before summing allowed amounts by member
You are given medical_claim_line as a pandas DataFrame: claim_line_id, claim_id, claim_version, frequency_code (1 original, 7 replacement, 8 void), member_id, service_start_date, procedure_code, allowed_amount, claim_status. Return total allowed_amount per member for service dates in one stated calendar month, counting each claim once at its surviving version and excluding any claim whose surviving version is a void. Multi-line claims must keep every line of that surviving version. Output columns: member_id, allowed_amount, sorted descending. Do not deduplicate on claim_id alone.
Approach
- Separate the two grains out loud before writing code: versions live at the claim level, dollars live at the line level. Every bug in this exercise comes from mixing them.
- Compute the surviving version per claim with a groupby transform of max over claim_version, then keep the lines whose claim_version equals that value. A transform keeps the frame at line grain, which a sort plus head(1) does not.
- Drop whole claims whose surviving version carries frequency_code 8. A void is not a zero-dollar line, it retracts the claim, so filtering rows rather than claims leaves the prior version's lines behind.
- Filter to claim_status 'paid' and state the assumption: denied, pended and reversed lines carry an allowed_amount that never became a liability, so including them overstates cost.
- Restrict service_start_date to the month boundaries, then groupby member_id and sum. Sort descending and return.
Worked solution 20 min
- Build a max-version lookup per claim_id with groupby('claim_id')['claim_version'].transform('max') and keep rows where claim_version equals it.
- From the surviving rows, collect the claim_ids whose frequency_code is 8 and drop those claim_ids entirely.
- Filter claim_status to 'paid' and service_start_date into the month window.
- Group by member_id, sum allowed_amount, sort descending, reset the index.
Follow-up
- A claim has versions 1, 7, 7 where the second replacement has fewer lines than the first. What does your code return and is that correct?
- How would you handle a claim whose lines span two calendar months at the boundary of the reporting window?
- The same logic has to run over 400 million lines in a warehouse. What changes, and what stays the same?
Report site activation to first randomization without hiding non-enrollers
study_site holds one row per (study_id, site_id): site_activation_date, which is NULL for a site selected but never activated, and site_status. study_subject_visit holds subject_visit_id, study_id, site_id, subject_id, randomization_ts (NULL for screen failures), visit_name, visit_number, actual_visit_date and visit_status, with one row per subject per protocol visit, so randomization_ts repeats across every visit of a randomized subject and a site that has screened nobody has no rows there at all. For one study_id and a stated data cut date, return per activated site the activation date, the first randomization_ts and the days between them, with activated sites that have randomized nobody still present. Add a study-level summary giving median days to first randomization and the share of activated sites with no randomization by day 90.
Approach
- Take the site universe from study_site, never from study_subject_visit. The visit table can only contain sites that have screened at least one subject, so a universe built from DISTINCT site_id there omits exactly the sites this metric exists to expose. Filter study_site to the study and to site_activation_date IS NOT NULL, then LEFT JOIN the per-site first randomization.
- Collapse the grain before aggregating anything on the visit side. The table repeats randomization_ts across every visit of a randomized subject, so any count taken at row grain is inflated by visits per subject. MIN(randomization_ts) per site is safe, COUNT is not.
- State the date boundary rule. randomization_ts is a timestamp and site_activation_date is a date, so a randomization at 23:40 local time can land on either side of a day boundary depending on the zone the timestamp is stored in. Cast once, deliberately, and say which zone.
- Use PERCENTILE_CONT(0.5) WITHIN GROUP (ORDER BY days) for the median and be explicit that it ignores NULLs, so it is a median over enrolling sites only. That is exactly why the non-enroller share is reported beside it rather than instead of it.
- Censor the day-90 denominator against the data cut. A site activated 40 days before the cut has not had 90 days to randomize, so it cannot be scored on that bar and belongs outside that denominator.
Follow-up
- The same site_id appears under two studies. What breaks, and what is the correct grain for this metric?
- Would you present this as a median, as a Kaplan-Meier curve of time to first randomization, or both, and what does the curve show that the median cannot?
- A site randomized one subject who withdrew at visit 2. Does that site count as enrolling here, and how does that differ from a randomized-and-retained measure?
Turn overlapping coverage spans into fractional member-month denominators
member_enrollment holds span_id, member_id, plan_id, product_type, effective_date and termination_date, which is NULL while the span is active. A member can hold several spans in a year, and back-dated plan changes make spans overlap. Return one row per calendar month of 2025 with total member-months, where a member contributes covered days in the month divided by that month's length, and a day covered by two overlapping spans counts once. Both span endpoints are inclusive. Collapse overlaps with window functions before joining a month calendar, and do not assume one span per member.
Approach
- Normalise the open end first. COALESCE(termination_date, DATE '9999-12-31') or clip to the reporting end, because a NULL termination_date makes every BETWEEN comparison unknown and drops exactly the members who are still covered.
- Merge overlapping spans per member before the calendar join. Order by effective_date, carry a running MAX of prior termination_date with a frame ending one row before, and open a new island where effective_date exceeds that running max plus one day, which keeps adjacent spans contiguous rather than splitting them.
- Clip each merged island to the reporting year, then cross join to a twelve-row month calendar and keep pairs that intersect.
- Compute covered days as LEAST(island_end, month_end) minus GREATEST(island_start, month_start) plus one, and divide by the actual length of that month rather than a flat 30, so February and the 31-day months are not distorted.
- Sum the fractions by month. Merging after the calendar join also works but forces a DISTINCT over member-days, which stops scaling at population size.
Worked solution 30 min
- CTE bounded: clip spans to 2025-01-01 through 2025-12-31 with COALESCE on termination_date, discarding spans that do not intersect the year.
- CTE merged: gaps-and-islands per member using LAG and a running MAX over preceding rows to collapse overlapping and adjacent spans.
- CTE months: twelve rows of month_start, month_end and days_in_month.
- Join merged to months on interval intersection and compute covered_days per pair.
- SUM(covered_days / days_in_month::numeric) grouped by month, ordered by month.
Follow-up
- Where does a continuous-enrolment filter with an allowable 45-day gap belong, and how does that change the island boundary rule?
- One human appears under two member_ids after a master person index merge. What does that do to member-months, and how would you detect it?
- How do you treat a span that terminates on the day it starts, and what does that row usually represent?
Power a readmission trial on a rare binary outcome
A care-transitions programme (pharmacist call plus a seven-day follow-up visit) will be tested on index inpatient discharges drawn from encounter, excluding planned admissions, acute-to-acute transfers, AMA discharges, and dispositions of expired or hospice. Baseline 30-day unplanned readmission on eligible stays is 15.8 percent. Leadership wants to detect a 1.5 percentage point absolute reduction, two-sided alpha 0.05, 80 percent power, 1:1 individual randomisation at discharge. Give the required index stays per arm, and the minimum detectable absolute effect if only 4,000 eligible stays per arm accrue in the study window.
Approach
- Write the two-proportion sample size formula and state its preconditions: normal approximation, two-sided test, equal allocation, and the outcome measured on index stays rather than on members, since one member can contribute several index stays.
- Plug in p1 = 0.158, p2 = 0.143, and (z_0.975 + z_0.80)^2 = (1.960 + 0.842)^2 = 7.849. Report the answer as index stays, and separately as the calendar time it implies given the observed monthly eligible volume.
- Invert the same formula for the fixed-N case: solve for delta with n = 4,000 per arm, and say whether you used pooled or arm-specific variance because the two answers differ by about 0.1 percentage points.
- Translate the MDE into the relative reduction it implies and hand it back to leadership before the study starts, so the question becomes whether that effect is worth running rather than whether the null result was a failure.
- Flag the two adjustments that will make the real number larger: if a member can appear more than once, cluster on member_id, and if the programme is delivered by unit or by discharging team rather than to individuals, an individual-level calculation is the wrong model entirely.
Worked solution 20 min
- Compute (1.960 + 0.842)^2 = 7.849.
- Compute the variance sum: 0.158 x 0.842 = 0.1330, 0.143 x 0.857 = 0.1226, total 0.2556.
- n per arm = 7.849 x 0.2556 / 0.015^2 = 7.849 x 1,136 = 8,916, so round to about 8,920 per arm.
- For the MDE at n = 4,000, solve delta = sqrt(7.849 x variance sum / 4,000); with arm-specific variance this gives 0.0221, with pooled variance at p = 0.158 it gives 0.0229.
- Express the MDE as a relative effect: 0.023 / 0.158 is about a 15 percent relative reduction.
Follow-up
- The same programme is delivered by discharge unit, not to individual patients. What changes in the calculation?
- How would you handle a member who has three eligible index stays during the study window?
- Leadership proposes powering on a composite of readmission or ED revisit instead. What does that buy and what does it cost?
Critique a denial rate slide before it is shown
A weekly slide says first-pass denial rate improved from 9.1 percent to 7.4 percent month over month. It was computed from medical_claim_line as rows with claim_status 'denied' divided by all rows with a received_date in the month. You cannot query anything. List every assumption the number rests on, restate the metric so two analysts computing it independently would get the same value, and give the three questions you would ask before the slide is presented.
Approach
- Work the grain first. The denominator counts all rows, so a claim resubmitted after a denial contributes its original line, its replacement (frequency_code 7) and possibly a void (8). Both numerator and denominator are inflated by exactly the claims most likely to have been denied, which makes the rate a function of resubmission behaviour rather than adjudication.
- Work maturity second. A line received late in the month may still be pended at extract time, and pended lines are neither paid nor denied. If pends resolve to denials later, the most recent month is understated by construction, which looks exactly like improvement. Ask for the paid-through date and the adjudication runout hold.
- Work the unit third. A denial rate on claim lines and a denial rate on claims are different numbers, and a single denied line on a twenty-line facility claim is a different operational event from a wholly denied professional claim. The spec has to pick one and say so.
- Work mix fourth. Denial reasons have different owners and different volumes: eligibility denials belong to enrollment operations, coding denials to provider relations. A shift in submission mix across providers, place of service or reason code moves the blended rate with no change in any component, so the restated metric reports by denial_reason_code group.
- Work precision last. A 1.7 point move is decisive on two million lines and meaningless on three thousand. The restated metric carries the denominator count, and a slide without it cannot be read.
Follow-up
- The rate is still down after version dedup and a 60-day hold. What is the next thing you check before anyone celebrates?
- Which of these problems would also affect a paid-amount series computed the same way?
- How would you present the restated number so the audience understands the prior month is provisional?
Pooled persistency fell but no one lost coverage
Pooled 12-month enrollment persistency fell from 0.78 to 0.66 for the cohort anchored in a single month. member_enrollment carries span_id, member_id, plan_id, product_type, effective_date, termination_date, termination_reason_code, dual_eligible_flag and region_code. The metric allows at most one gap of 45 days or fewer. Product mix in that anchor month was not stable. Determine how much of the fall is real disenrollment rather than span bookkeeping or mix, and deliver a persistency series a contract owner could act on.
Approach
- Inspect the query's unit of analysis first. Spans are not members, and a benefit or plan change closes one span and opens the next on the same day, so any logic that treats a non-null termination_date as loss of coverage counts an administrative event as churn.
- Rebuild member-level coverage by unioning all spans per member and merging adjacent or overlapping ones, then apply the 45-day gap rule to the merged intervals rather than per span.
- Cut the terminations by termination_reason_code. plan_change and eligibility_redetermination have entirely different meanings for a contract, and death is not churn you can address.
- Split by product_type and stop pooling. Commercial open enrollment and managed medicaid redetermination produce structurally different churn on different calendars, and the pooled average of the two is a number that describes nobody.
- Compare the anchor month to the same month in the prior year rather than to the adjacent month, because enrollment is strongly seasonal and an anchor month sitting on an open-enrollment or redetermination boundary is not comparable to its neighbour.
- Apply the Kitagawa decomposition across product_type to separate how much of the 12 point fall is mix, meaning the anchor cohort simply contained more of a high-churn product, from how much is within-product deterioration.
Follow-up
- Why 45 days, and what would change if the allowable gap were 30 or 60?
- A member terminates and re-enrolls 90 days later under a different plan_id. Are they retained? Defend your answer against the opposite one.
- What guardrail would catch someone improving persistency by declining to enroll members likely to churn?
For someone who can already write the query and train the model but stalls when asked what to measure or whether a change is worth making. Metric definition and case structure come first; the technical work is kept as maintenance rather than the centre of the week.
Prepare, practise & reflect
One practical outcome each day. Spend longer where you need it.
0 / 7 done01Metric anatomy
- For three products you use daily, write one primary metric, two input metrics that plausibly move it, and one guardrail that would catch a cheap way of moving the primary at the cost of the product.
- For one of them, specify the metric precisely enough that two analysts would return the same number: numerator, denominator, unit of observation, time window, and how returning and deleted accounts are treated.
- Pick a ratio metric and write what happens to it when the denominator shrinks for reasons unrelated to the numerator, with a concrete example of that happening.
Deliverable: A one-page metric tree for one product, with the primary metric written as an unambiguous spec.
Practice prompt ↗Practice prompt ↗Worked solution ↗02Diagnosing a drop without guessing
- Take the prompt "weekly active users fell 8 percent week over week" and write the segmentation plan before proposing any cause: platform, region, tenure cohort, acquisition channel, and whether the movement sits in the numerator or in a changed denominator.
- List the instrumentation failures that manufacture fake drops (a client release that stopped firing an event, a bot filter change, a shifted date boundary or timezone) and write the query that rules out each one.
- Rehearse stating the boring explanations first, seasonality and day-of-week composition, before reaching for a product cause.
Deliverable: A drop-diagnosis checklist short enough to recite from memory in under a minute.
Practice prompt ↗Practice prompt ↗03Should we build it
- Take a feature idea and write it as a bet: what you believe is true, what would have to be true for it to pay off, the metric that would confirm it, and the effect size that would justify the engineering cost.
- Size the opportunity top-down and bottom-up, then reconcile the two numbers in writing instead of quoting whichever is friendlier.
- Write the counter-metric that would make you kill the feature even if it wins on the primary metric.
Deliverable: A one-page product memo ending in a decision rather than a list of considerations.
Practice prompt ↗Practice prompt ↗04The places aggregate numbers lie
- Construct a Simpson's paradox numerically: two segments where the treatment wins within each segment yet loses overall, and identify the shift in segment weights that causes it.
- Take a heavy right-tailed quantity such as revenue per user and write why the mean is the wrong summary, which percentile you would report instead, and what a moving mean with a stable median tells you.
- Write your definition of a session for the product from day one, then name two real behaviours it misclassifies.
Deliverable: One page holding a worked Simpson's paradox table and a session definition with its two known failure cases.
Practice prompt ↗Practice prompt ↗Worked solution ↗05Technical maintenance, aimed at metrics
- Solve four timed SQL prompts that all end in a ratio metric, so the question of grain stays live in every answer.
- Compute a 95 percent confidence interval for a proportion on a small sample, and state why the normal approximation is unreliable when either np or n(1 minus p) falls below roughly 10, along with which interval you would use instead.
- Take one metric from your day-one tree, write the query that computes it correctly, then write the query that computes it wrong in the most plausible way and explain how you would notice.
Deliverable: Four solved prompts plus a matched correct and plausible-wrong query for one metric.
Practice prompt ↗Practice prompt ↗06Turning engineering work into data science stories
- Write three project stories as situation, decision, trade-off, outcome, each carrying one number and one thing you got wrong.
- For the story you will lead with, prepare an answer to "what would you do differently" that names a decision you made, not a constraint you were handed.
- Practise the sentence that reframes a systems project as a question project: the question the work answered, ahead of the pipeline it shipped.
Deliverable: Three written stories with the lead story delivered aloud and timed under four minutes.
Practice prompt ↗Practice prompt ↗07Mock case and gap list
- Run a 40-minute mock case with someone playing a product manager who pushes back on your metric choice, and record it.
- Listen back and mark every moment you proposed a solution before the success metric existed.
- Rewrite those moments as the question you should have asked, and rehearse the first 90 seconds of the case until scoping comes before solving.
Deliverable: A recorded case plus a rewritten opening 90 seconds.
Practice prompt ↗Worked solution ↗Expand any day for tasks and deliverables. Your progress is saved on this device.
Saying no well is a senior skill and it is rarely rehearsed. Think of a time you told someone their analysis was not worth doing, or that the experiment could not answer their question at the sample size available. Explain what you offered instead. Refusal without an alternative reads as obstruction rather than judgement.
Describe a time you had to explain a complex statistical result to a n…
Describe a time you had to explain a complex statistical result to a non-technical stakeholder.
Approach
- Pick a story where you drove the decision, not one where you observed it.
- Quantify the outcome, including what you would not claim credit for.
- Name the disagreement or constraint, and how you resolved it with evidence.
Follow-up
- What did you decide not to do, and why?
- What would you do differently if you ran that project again?
Defend a null result against a programme sponsor
A care management programme enrolled the top 1 percent of members by prior-year allowed spend. The sponsor's deck shows allowed PMPM for enrollees falling 34 percent from the year before enrollment to the year after, and asks for budget to triple the programme. You rebuild the evaluation with a concurrent comparison group selected by the identical spend rule in the same period. The difference-in-differences estimate is a 3 percent reduction with a confidence interval spanning zero. Deliverable: how you present this, to whom, in what order, and what you propose next.
Approach
- Name the probe: whether you can deliver a finding that costs somebody their programme without softening it into uselessness or creating an adversary who routes around you next time.
- Lead with the mechanism, not the verdict. Show the comparison group's own unadjusted drop, which will be large, because a cohort selected on an extreme of the outcome regresses toward the mean whether or not anyone intervenes. The sponsor's 34 percent is mostly that, and it is a property of the selection rule rather than a criticism of their clinicians.
- Give the sponsor the finding privately before it appears in any deck their leadership sees. Being surprised in a room is what turns a methods disagreement into a political one.
- State the estimate with its interval and say what it rules out as well as what it fails to establish. A 3 percent point estimate whose interval crosses zero is not evidence of no effect; it is insufficient power to separate a modest effect from none, and those are different claims.
- Arrive with a design rather than only an objection. Propose a regression discontinuity at the enrollment threshold if the rule is applied sharply, or a randomised rollout across the next wave of eligible members, and state the sample size needed to detect the effect size the sponsor believes in.
Follow-up
- The sponsor says withholding the programme from a comparison group is unethical. What do you propose instead?
- Leadership wants one number for the board next week. What do you give them?
- What result would change your mind and make you believe the 34 percent?
Disagree with a product manager about an adherence nudge
A product manager proposes shipping a refill-reminder feature to the whole member base, citing an internal analysis: members with 12-month proportion of days covered at or above 0.80 had 31 percent fewer admissions than members below it. The roadmap date is three weeks out and engineering is scoped. You believe the comparison builds survival and continuous coverage into the exposure definition, and is separately confounded by the kind of member who refills on time. Deliverable: what you say in the room, what you send afterwards, and the smallest study you would accept as sufficient to ship.
Approach
- The probe is whether you can be specific and non-territorial at once. A disagreement that arrives as 'the analysis is flawed' costs you the room; one that names a mechanism and offers a cheaper path keeps it.
- Name the two defects separately, because they have different fixes. Classifying a member as adherent over 12 months requires them to stay alive and stay covered for those 12 months, and that guaranteed event-free interval is assigned to the adherent group. Separately, members who refill on schedule differ from those who do not in ways claims never record.
- Show rather than assert. Rerun the same comparison as a landmark analysis: classify adherence over days 1 to 90, start follow-up at day 91 for everyone still enrolled and event-free, and report how much of the 31 percent survives.
- Separate the association claim from the intervention claim out loud. Nothing in the analysis speaks to whether a reminder changes refill behaviour, which is the actual product question and is separately testable.
- Offer the shippable path: a randomised holdout on a subset with proportion of days covered as the primary endpoint, powered on the plausible effect of a reminder rather than on the 31 percent, with a stated read date.
Follow-up
- The landmark rerun still shows a 20 percent difference. Do you ship?
- The product manager says a holdout delays launch. How do you cost that argument?
- What primary endpoint do you choose, and why not admissions?
- 01
Describe a time you had to explain a complex statistical result to a non-technical stakeholder.
- 02
A care management programme enrolled the top 1 percent of members by prior-year allowed spend. The sponsor's deck shows allowed PMPM for enrollees falling 34 percent from the year before enrollment to the year after, and asks for budget to triple the programme. You rebuild the evaluation with a concurrent comparison group selected by the identical spend rule in the same period. The difference-in-differences estimate is a 3 percent reduction with a confidence interval spanning zero. Deliverable: how you present this, to whom, in what order, and what you propose next.
- 03
A product manager proposes shipping a refill-reminder feature to the whole member base, citing an internal analysis: members with 12-month proportion of days covered at or above 0.80 had 31 percent fewer admissions than members below it. The roadmap date is three weeks out and engineering is scoped. You believe the comparison builds survival and continuous coverage into the exposure definition, and is separately confounded by the kind of member who refills on time. Deliverable: what you say in the room, what you send afterwards, and the smallest study you would accept as sufficient to ship.
Is this an official BridgeBio interview guide?
No. It is PracHub's own research and practice material for the Data Scientist role at BridgeBio. Rounds and questions reflect what candidates have reported, not a process BridgeBio has published, and they change over time. Confirm the current format and scope with your recruiter.
PracHub interview research ↗How long does the interview process typically take?
The process is comprehensive, often involving several rounds of interviews. While timelines can vary, the process is generally well-paced and respectful of your time.
PracHub interview research ↗What is the most important factor in the final decision?
Beyond technical capability, BridgeBio looks for "mission fit." They want to see that you are genuinely invested in the work of curing genetic diseases and that you possess the ownership mindset to drive that mission forward.
PracHub interview research ↗Is the technical assessment difficult?
Expect a rigorous process. The difficulty is high because the work itself is high-stakes; however, the questions are designed to be fair and relevant to the actual work you would be doing on the team.
PracHub interview research ↗Does the company offer remote work?
Specifics regarding location and hybrid arrangements are typically discussed during the recruiter screen. Ensure you clarify these expectations early in the process.
PracHub interview research ↗Sources & methodology 3 sources ↗
No official company page is cited. Rounds and questions come from candidate reports and PracHub editorial material; each source shows the date it was read.
- 01PracHub interview research ↗
PracHub editorial research into this company and role, maintained with this guide. Candidate-reported, not an employer publication.
PracHub page · Accessed 2026-09-22 - 02PracHub Data Scientist practice ↗
Cross-company practice questions for this role.
PracHub page · Accessed 2026-09-22 - 03PracHub interview preparation framework ↗
The framework the preparation plan follows.
PracHub page · Accessed 2026-09-22
Explore related engineering environments and compare the preparation focus.
Veracyte Data Scientist Interview Questions & Guide 2026
Causal-inference exercises for Veracyte data scientist prep: difference-in-differences, matching, instrumental variables, and knowing when observational data simply cannot answer the question asked.
Zoetis Data Scientist Interview Questions & Guide 2026
Metric-diagnosis practice for Zoetis data scientist candidates: a number moves week over week and you work out why, splitting by segment, ruling out a logging or release change, and separating a mix shift from a real change in user behaviou
Vizient Data Scientist Interview Questions & Guide 2026
Communication practice for Vizient data scientist candidates: turn an analysis into a recommendation, name the uncertainty honestly, and answer the follow-up a skeptical stakeholder will raise.
Vibrant Emotional Health Data Scientist Interview Questions & Guide 2026
Case practice for the Vibrant Emotional Health data scientist interview, where the prompt is deliberately underspecified and your first move is scoping it into something measurable.